Acasti completes patient enrollment in Phase 3 STRIVE-ON trial of GTX-104

Patient Enrollment Completion: Acasti Pharma has completed patient enrollment for its Phase 3 STRIVE-ON safety trial, which involves 100 patients hospitalized for aSAH.

Trial Details: The STRIVE-ON trial is a prospective, open-label, randomized study comparing GTX-104 with oral nimodipine, conducted across approximately 25 hospitals in the U.S.